Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab in CNS Lymphoma
NCT06922604Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Jul 2025
- Primary completion
- Jan 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glofitamab in central nervous system lymphoma, sponsored by City of Hope. Primary endpoints: Incidence of grade 3 or higher non-hematologic toxicity at 6 weeks, Incidence of grade 3 or 4 thrombocytopenia associated with grade >= 3 bleeding at 6 weeks and 6 more. Started Jul 2025; status: suspended.
02
Drugs
glofitamab
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT06922604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922604.